HBK Sorce Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

HBK Sorce Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$348K	Buy	11,167 +20	+0.2%	+$476	0.01%	453
2025 Q4	$272K	Hold	11,147	–	–	0.01%	499
2025 Q3	$237K	Sell	11,147 -43	-0.4%	-$884	0.01%	528
2025 Q2	$243K	Buy	11,190 +43	+0.4%	+$1.01K	0.01%	507
2025 Q1	$270K	Hold	11,147	–	–	0.01%	477
2024 Q4	$233K	Hold	11,147	–	–	0.01%	507
2024 Q3	$222K	Hold	11,147	–	–	0.01%	519
2024 Q2	$173K	Hold	11,147	–	–	0.01%	533
2024 Q1	$178K	Buy	11,147 +38	+0.3%	+$573	0.01%	569
2023 Q4	$187K	Hold	11,109	–	–	0.01%	531
2023 Q3	$130K	Sell	11,109 -38	-0.3%	-$508	0.01%	533
2023 Q2	$150K	Buy	11,147 +38	+0.3%	+$547	0.01%	550
2023 Q1	$184K	Sell	11,109 -11,543	-51%	-$190K	0.01%	548
2022 Q4	$421K	Buy	22,652 +11,543	+104%	+$178K	0.01%	447
2022 Q3	$143K	Hold	11,109	–	–	0.01%	478
2022 Q2	$78K	Hold	11,109	–	–	0.01%	447
2022 Q1	$92K	Hold	11,109	–	–	0.01%	531
2021 Q4	$75K	Hold	11,109	–	–	﹤0.01%	579
2021 Q3	$59K	Hold	11,109	–	–	﹤0.01%	579
2021 Q2	$64K	Hold	11,109	–	–	﹤0.01%	582
2021 Q1	$51K	Hold	11,109	–	–	﹤0.01%	539
2020 Q4	$37K	Hold	11,109	–	–	﹤0.01%	497
2020 Q3	$33K	Hold	11,109	–	–	﹤0.01%	448
2020 Q2	$51K	Hold	11,109	–	–	﹤0.01%	430
2020 Q1	$43K	Hold	11,109	–	–	﹤0.01%	390
2019 Q4	$42K	Hold	11,109	–	–	﹤0.01%	434
2019 Q3	$59K	Hold	11,109	–	–	0.01%	401
2019 Q2	$43K	Hold	11,109	–	–	﹤0.01%	409
2019 Q1	$57K	Hold	11,109	–	–	0.01%	424
2018 Q4	$21K	Sell	11,109 -10,000	-47%	-$28.6K	﹤0.01%	381
2018 Q3	$80K	Hold	21,109	–	–	0.01%	394
2018 Q2	$66K	Hold	21,109	–	–	0.01%	381
2018 Q1	$50K	Hold	21,109	–	–	0.01%	374
2017 Q4	$83K	Hold	21,109	–	–	0.01%	385
2017 Q3	$53K	Hold	21,109	–	–	0.01%	313
2017 Q2	$58K	Buy	+21,109	New	+$44.1K	0.01%	301
2017 Q1	–	Sell	-21,109	Closed	-$26.9K	–	330
2016 Q4	$22K	Hold	21,109	–	–	﹤0.01%	290
2016 Q3	$23K	Hold	21,109	–	–	﹤0.01%	283
2016 Q2	$15K	Hold	21,109	–	–	﹤0.01%	272
2016 Q1	$25K	Buy	21,109 +10,000	+90%	+$15.5K	0.01%	245
2015 Q4	$27K	Hold	11,109	–	–	0.01%	216
2015 Q3	$33K	Hold	11,109	–	–	0.01%	193
2015 Q2	$46K	Buy	+11,109	New	+$44.3K	0.02%	188

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HBK Sorce Advisory's CPRX Position: Q1 2026 in Review

HBK Sorce Advisory increased its Catalyst Pharmaceutical (CPRX) stake by 0.18% in Q1 2026, buying an estimated $476 and bringing the position to 11,167 shares worth $348K. The position accounts for 0.01% of the portfolio, ranked #453.

HBK Sorce Advisory first reported a position in CPRX in Q2 2015 and has held it in 43 quarters since. The position peaked at $421K in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

HBK Sorce Advisory held 11,167 shares of Catalyst Pharmaceutical worth $348K as of Q1 2026.
HBK Sorce Advisory bought 20 Catalyst Pharmaceutical shares in Q1 2026, an estimated $476.
Catalyst Pharmaceutical made up 0.01% of HBK Sorce Advisory's portfolio in Q1 2026, its #453 holding.
HBK Sorce Advisory first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 43 quarters since.
HBK Sorce Advisory's Catalyst Pharmaceutical position peaked at $421K in Q4 2022.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.